Political News and Conservative Analysis About Congress, the President, and the Federal Government
fell by over 12% in one day, its largest decline since last August. Inspire Medical Systems, which makes an implanted medical device to treat sleep apnea, also fell by nearlyEli Lilly sells tirzepatide under the name Mounjaro for Type 2 Diabetes and Zepbound for obesity.
Patients with severe sleep apnea can have hundreds of episodes in one night, increasing the patient’s risk for high blood pressure, heart disease, and strokes., the lead author of the study and a professor of medicine at the University of California San Diego School of Medicine, said the drug could revolutionize treatment of OSA because it is much more accessible than current machines or device-based interventions, which depend on consistent use.
“It means we can offer an innovative solution, signifying hope and a new standard of care to provide relief to countless individuals and their families,” said Malhotra. “This breakthrough opens the door to a new era of OSA management for people diagnosed with obesity, potentially transforming how we approach and treat this pervasive condition on a global scale.”
Malhotra also said that tirzepatide is beneficial because it targets the root causes of the disorder rather than solely symptoms.According to data from the discount prescription company GoodRx, both Mounjaro and Zepbound cost over $1,000 for a monthly dose.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Eli Lilly shares should be up on its latest news, plus Nvidia keeps rollingEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Apple, Coinbase, Yext fall premarket; GM, Eli Lilly riseApple, Coinbase, Yext fall premarket; GM, Eli Lilly rise
Read more »
Stocks making the biggest moves premarket: Eli Lilly, General Motors, ShopifyThese are the stocks posting the largest moves in premarket trading.
Read more »
A successful Alzheimer's drug will help Eli Lilly join the $1 trillion clubFor Eli Lilly to become the first drugmaker to soon reach that milestone market cap, it will need drugs beyond GLP-1s.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »